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As regenerative medicine products scale up, researchers turn their attention beyond the ongoing technical challenges
of collecting, preserving and delivering gene- and cell-based products to manufacturing and business operations,
including process control, automation, supply chain and logistics, and the viability of business model alternatives.
Assessing readiness for clinical use, however, requires an integrated assessment across all of these crucial components,
including how well they fit together (or not), how synergies might enable platform opportunities and, critically,
what kinds of infrastructures should be created to support a range of cell- and tissue-based products and services.
Infrastructures reveal the way that futures are anticipated while shaping things in the present [1]. Yet large investments,
including major changes to physical facilities, organizational structures and processes, can make it difficult to change
things later [2]. There is much at stake, then, for institutional readiness in terms of having robust, yet adaptable,
infrastructures.
We suggest that analysis of the spatial and temporal aspects of infrastructure is a useful way to take a more
integrated view across all manufacturing phases, participants and components of regenerative medicine when
assessing institutional readiness. We use the concept of institutional readiness [3] as a way to frame the interrelation
of material technologies, knowledge bases and social and economic factors affecting translation. We focus on the
UK and use the term ‘advanced therapy medicinal products’ to encompass the variety of cell-, tissue- and gene-based
therapies that involve altering biological characteristics. Although it is self-evident that there are specific spatial and
temporal needs for different cell types and delivery models, we discuss major planning issues that all share.
Our comments derive from an ongoing Wellcome Trust-funded workshop series organized by the authors.
The workshops bring together social scientists and biomedical professionals actively developing cell- and tissue-
based products with the aim of learning how intended applications and commercialization strategies interact
with knowledge production systems and the broader socioeconomic environment. Ongoing workshops center
on emerging technological, financial and organizational infrastructures and complex production and scale-up
techniques and how these interact with regulatory and policy arenas as well as the development of novel business
models and valuation strategies. A core group of seven social scientists, all with expertise in science and technology
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studies, attend all workshops in the series. Each core member has an active portfolio of empirical research regarding
cell- and tissue-based products, through which they contribute to the continuing dialogue. Each workshop entails
presentations from two invited experts who are actively developing or supporting therapeutic interventions, with
in-depth, interactive discussions of specific challenges they face regarding scale-up. We aim to illuminate challenges
that may be less discussed, yet are common across various applications, as well as unique issues as new research
and production alternatives appear. In this article, the specific contributions and details of individual cases remain
anonymous. Our analysis represents the comments of the authors only. This commentary also draws upon related
research conducted separately by the individual authors that involves interviews with professionals working on
engineered skin, blood and muscle and on clinical translation of gene editing, induced pluripotent stem cells and
3D printing in the UK [4–7]. Signed informed consent was received from all interviewees in these studies prior to
interview.
Spatiotemporal readiness
It is important to consider spatiotemporal readiness as a key dimension of overall organizational readiness. Successful
translation of regenerative medicine in clinical contexts requires attention to the interrelatedness of the ‘where’ and
‘when’ questions with costs, capacities and effective outcomes. A recent collaborative report identifying engineering
processes and logistics challenges for cost-effective and reproducible manufacturing highlights how space, speed,
cost and quality issues cannot be viewed separately, as they mutually shape and inform each other [8]. This view
was echoed in our workshops through examples in which apparently mundane logistical where and when issues,
such as the design and layout of laboratory and production spaces and how people, materials and information pass
through them, proved non-trivial in the effective delivery of cell- and tissue-based products.
Effectively achieving spatiotemporal readiness is important for the economic and technical success of these
endeavors but also has important bioethical implications. Efficient delivery could make therapies available sooner
and more cost-effective for end users and, by incorporating a fairness framework for manufacturing capacity
allocation, increases the likelihood that the benefits of regenerative medicine will be available for all who need it
most [9]. Spatiotemporal readiness enhances product integrity, benefiting manufacturers and human subjects who
volunteer for clinical trials. However, appropriate spatiotemporal procedures are highly context-specific and can
vary by technology, patient population and economic environment.
Importantly, spatiotemporal readiness encompasses both actual and anticipated where and when issues. Visions of
future spatiotemporal infrastructures that later prove inappropriate can impede effective delivery. Multiple potential
business models are arising [10,11], each including an anticipated spatiotemporal model. Any business model or
manufacturing process that does not accurately account for the spatiotemporal organization of the clinics in which
therapeutic products would be applied could face difficulties, especially if the process design has locked-in elements
that are poorly aligned with clinical practice. This is further complicated by the diversity of product and patient
contexts.
To date, discussion of aligning commercial, regulatory and clinical factors too often implies that commer-
cialization is a linear process, and that readiness will allow an acceleration through various steps [6]. Examining
spatiotemporal aspects of translation is one way to show how this linear model can be misleading, as time lines
take longer than anticipated and, importantly, become iterative through movements within and between preclinical
trials and market authorization. Successful acceleration here requires something other than simply speeding forward
toward a chosen goal.
Spatiotemporal readiness before the clinic
International initiatives for manufacturing scale-up are considering multiple levels of scale, from the organization of
laboratory space to the geographies of national and international production and use. Although many institutes are
offering current GMP facilities for storage, testing and processing, some national-level and government-supported
initiatives, such as Canada’s Centre for Commercialization of Regenerative Medicine and the UK Cell and Gene
Therapy Catapult, offer centralized facilities. Regulatory-compliant modular spaces and consulting services are
established to bridge nascent innovations from academic inventors and commercial entities with industrialization
expertise. The UK catapult, for example, has both a 1200 m2 development center with a configurable pod system
to replicate users’ processes and a 7200 m2 manufacturing center with GMP-compliant but segregated modules
designed for flexible use. In such contexts, companies must decide whether locating their manufacturing work in
such sites and utilizing these facilities is preferable to developing and using their own operations. Larger companies
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are more likely to use in-house facilitates and acquire technology from start-ups. Product sponsors may be operating
out of academic centers or facilities acquired in company purchases and must decide whether and how to reorganize
space to meet requirements for the products they intend to make.
Such decisions may be framed by the legacies of previous company acquisitions, as the many takeovers and
mergers seen in the sector lead to companies holding a portfolio of spaces and facilities that may or may not map
onto their priorities at any particular time. Emerging infrastructures may be built upon existing infrastructure,
which possibly brings forward the risk that old constraints may still be in place and can be insufficient to deal
with emergent issues and market conditions. Other cases may see the creation of de novo infrastructure or hybrid
infrastructures that seek to combine the new with the existing. Such novelty can be costly and more time-consuming.
It also retains the risk that the first to create a new mode of operating may or may not be the one who reaps the
benefits, as novel radical approaches become reproduced by others once initial problems have been worked through.
Alternatively, first movers may not end up developing what becomes the industry standard and be left with outdated
legacy infrastructures. As with many therapeutics, first in class is rarely best in class.
The geographical location of these facilities is also important, as locations near major transport links and areas
with readily available ancillary services create an advantage. International transportation can also prove burdensome,
as logistical boundaries and regulatory jurisdictions provide additional barriers. One eye-catching example occurred
when the team producing the first tissue-engineered trachea for transplant was turned away from Bristol Airport in
2008, as easyJet representatives refused to allow the biological material onto the flight, despite assurances in advance
it would be allowed, necessitating that £14,000 be spent on a private plane to make the 16 h window for use.
Such examples highlight the necessity for regenerative medicine infrastructures to fit within existing infrastructures
for transport and other needs. In the UK, future border issues could be exacerbated by the assembly of new
administrative borders with EU countries and import and export of biological materials. Even within a single
country, deciding how and when to transport material is key. The timing of delivery of a therapeutic product to
a patient can be critical, but the appropriate timing of a delivery may be contingent on a patient’s complex and
variable condition [12]. For example, autologous keratinocyte-based engineered skin should be transplanted within
24 h of leaving the manufacturing facility. But if a patient’s condition deteriorates during the transit period such
that surgery is not possible within that window, the patient’s skin, the company’s resources and critical time for
healing are all wasted.
Within production facilities, the size and modularity of manufacturing spaces affect workflow, labor, materials
and sequencing. For smaller facilities, having fewer higher-grade clean rooms creates problems with scheduling and
sequence of events. One workshop attendee described the challenges of deriving GMP induced pluripotent stem
cell lines, which necessarily require open cell culture and thus can monopolize a grade B clean room of any size for an
extended period. Other issues include mundane but necessary tasks like cleaning and maintenance. Such challenges
demand a careful choreography of laboratory space usage in planning sequential and side-by-side activities, which
can have significant financial implications when these where and when issues are misaligned. Choice of culture
system types and automation also must be considered [13,14]. Closed systems can allow manufacturing to move from
grade B to C/D clean rooms, with a likely reduction in cost. Some manufacturing steps can be automated, but
there is currently little speed advantage over manual processes. Automated processing still requires skilled operators.
As a result, manufacturing remains expensive in terms of high-cost skilled labor time. Many steps still cannot be
automated, nor can they be undertaken in fully closed systems, because of the need to feed and sample cells. There
is also a relation between closed systems and the cost of labor and reagents.
Spatiotemporal readiness for integrating manufacturing with the clinic
The way existing facilities map onto the anticipated spatiotemporal dimensions of a business model is also
important. Such models have clear spatial economics at the core of their vision that frame where and when priorities.
Many manufacturers, including large pharmaceutical companies, favor a production model based on conventional
pharmaceuticals, with a limited number of manufacturing sites, each supplying a standardized advanced therapy
product to a wide territorial range. This keeps the cost of expensive manufacturing equipment and sites (e.g., GMP-
compliant) down and allows centralized quality management, batch control and sign-off by qualified persons. This
model suits standardized products, whether allogeneic therapies or some autologous therapies where each sample
is processed in a comparable way, such as chimeric antigen-receptor T-cell therapies. For many products, localized
on-site manufacturing is impractical. The volume and configuration of space would be difficult for many existing
facilities; the skills needed for processing, maintenance and even data analytics may not be available; and quality
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control capacity in healthcare facilities is not oriented toward this work. Some clinics may have the capacity for
tasks like drug compounding or certain forms of chemistry, but fewer could effectively deliver processing and
distribution of live biomaterials. Those hospitals with existing capacity in precedent procedures, such as bone
marrow transplants, may face less disruption in introducing cell-based transplants. However, in many cases there
may not be enough patients at clinical sites to warrant investing in personnel, equipment and meeting GMP
requirements to make investment in distributed models viable.
Techniques of additive manufacturing, however, have given a renewed impetus to redistributed manufacturing
in health care [15]. One option is highly localized, ‘surgeon-led’ 3D printing of cellular constructs. This would
allow very near-patient manufacturing, which can be important for products with a very short shelf life or those
that are not amenable to the freezing and thawing cycles needed for more centralized manufacturing strategies.
However, the feasibility depends a great deal on the regulatory classification of such products. If bioprinting can be
considered minimal manipulation of the cells, then a bio-printed construct might be regarded as a transplant and
its products as the practice of medicine, but it is more probable that regulators will regard the construct as a product
under the advanced therapy medicinal product regulations (most likely as either ‘tissue-engineered medicines’ or
combination products) [16]. In this case, the same prohibitive cost implications of localized manufacture discussed
earlier are likely to apply, with each clinic counting as a discrete manufacturing site. As a result, this pathway may be
restricted to one-off patient-specific implants delivered as ‘hospital exemptions’ or ‘hospital specials.’ These bypass
the requirement to secure market approval as a medicinal product, but not the requirement for adequate quality
management during manufacture, while also limiting the scalability of the technique.
An alternative spatial configuration is the ‘hub and spokes’ approach where implants are designed, using computer-
aided design software, in a centralized facility with centralized quality control and then transmitted to local sites for
bioprinting. This looks more like conventional manufacturing in terms of scalability and manufacturing site costs
but raises issues regarding the security of transmitted computer-aided design information, which is unavoidably
confidential medical data about a patient, and the distribution of liability among the various computer engineers,
bioprinter operators, qualified persons, surgeons and manufacturers of components such as bio-inks and scaffolds
that may be utilized to create the final implant [16]. In these distrusted manufacturing models, it is not the bio-
printed implant that is commercialized but the equipment, protocols and capacity to produce the implant, which
is a rather different business model. Readiness here transcends individual institutions and involves a higher-level
issue of the capacity of national legal systems (regulation but also issues of manufacturing liability) to support or
constrain additive manufacturing.
Another model that could apply to both bioprinting and more conventional regenerative medicines involves the
creation of specialist centers of excellence (mainly university hospitals). This approach has (some of ) the benefits of
centralization but is more distributed. Here it would be important to ensure the physical separation of the hospital
from the manufacturing site. This centers-of-excellence model requires less upskilling of healthcare staff than a
general distribution model and can be used as a test bed to identify key drivers of institutional readiness and work
out how best to align academic, industry and hospital systems, with a view to rolling this knowledge out to other
sites in the future. This is the approach currently being pursued by the three advanced therapy treatment centers in
the UK that operate within the framework of the National Health Service but span academia, small biotechnology
companies and pharmaceutical multinationals [17]. Whatever model is adopted will have profound implications for
the development pipeline adopted by companies and their collaborators. As infrastructures become stabilized in
particular places, this will dictate the temporal flow of products through these manufacturing systems and place
constraints on life cycle management and the creation of next-generation products.
Spatiotemporal readiness and the economics of clinical practice
It is also vital that spatiotemporal aspects of the operations and business models of hospitals are assessed together
with those of the product sponsors. Key issues include where procedures will be performed, how much investment
will go into adopting new technologies and the burdens of modifying facilities to support them. The high costs
associated with one-off complex therapies do not align well with the periodicity of healthcare budgets, which
typically have fixed annual limits.
In many countries, hospital cost and revenue models are rapidly changing with the uptake of value-based models.
This shift from cost-per-unit thinking to one contingent on clinical outcomes aims to balance healthcare costs
with quality, with risk-sharing contracts negotiated between payers and product suppliers. Value-based contracts
are being used for high-cost therapies with highly variable outcomes, such as gene therapies [18,19]. Yet this poses
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Table 1. Challenges associated with spatiotemporal readiness.
Key planning themes Core potential issues
Laboratory design and use Efficient use of space; availability of space at the right time; appropriate sizing for application at
hand; maintenance scheduling.
In-house or external manufacturing
facilities
Cost; flexibility; speed to start; control and longevity.
Movement between sites Speed and shelf life; security; border crossings; trade and regulatory hurdles; route reliability.
Adoption of automated systems Deciding when a process is ready to be locked into automation may sacrifice flexibility; securing regulatory
approval; potential for portability of closed systems and required expertise.
Clinic integration and proximity What level of integration is appropriate for each specific product and each specific clinic; investments and
expertise requirements; when to enter the clinic.
Regulatory alignment Regulatory category fit; timing of submission; proactive actions for undefined future pathways; unique
production complexities (e.g., distributed additive manufacturing).
Payment Structuring reimbursement systems with the rhythms and needs of both companies and clinics; (mis)alignment
of therapeutic impact and payment model (e.g., with value-based systems).
particular challenges for regenerative medicine. Outcomes may take considerable time to become apparent for some
advanced therapy medicinal product treatments and are more difficult to measure than non-cell-based interventions.
This stretches the time line to assess success far beyond the time of treatment, with implications for healthcare
institutions and payers as well as product sponsors [7]. Furthermore, recent adoption of alternative ’real-world
evidence’ (used in review of fast-tracked regenerative medicine advanced therapies in the US and elsewhere) calls for
monitoring data through patient registries for years post-treatment. How government and commercial payers will
build and utilize such evidentiary alternatives to conventional proofs of efficacy and safety will be key to value-based
contract negotiations.
Time lines for fund flows are also affected, with differing implications for various stakeholders. Alternative
payment schemes have been proposed for high-cost treatments with potentially highly variable outcomes. Annuity
or staggered payments involve an instalment time line that can be preferable from a payer’s perspective to spread
risk over time [20]. However, such payments may be less amenable to cash–poor small- and mid-size enterprises
needing rapid returns to satisfy investors. Value-based payments based on clinical performance also introduce
uncertainty for any product sponsor, as the time line and level of payment may be harder to predict and may not
meet initial expectations, depending upon outcome. Such possibilities highlight the relationship between business
model choices and anticipated payment time lines, as assumptions of future market conditions shape decisions
made in the present. Alternative payment schedules may also cause problems for both payer and healthcare facility
financial reporting using existing cost accounting infrastructures [18]. Novel infrastructures for tracking patients,
monitoring outcomes and distributing financial reward or liability will thus require further analysis, development
and investment. At present, it is unclear who should do this and how such infrastructures should be governed. This
may require novel forms of public–private partnership.
To address these infrastructure misalignments, both healthcare institutions and innovators need to be resilient,
agile and willing to change. However, this may conflict with the need to standardize and build viable platforms and
requires attentiveness to what processes or ways of thinking become locked in, for how long and what impact this
may have. As such, questions of where and when to standardize or be adaptive arise.
Conclusion
Our discussions with researchers, both in workshops and individual projects, made clear the ways both actual and
anticipated spatiotemporal issues shape, enable and constrain actions. We urgently need to take where and when
questions seriously and to recognize their complexities as nonlinear processes. In Table 1, we present some of the
key themes institutions planning commercialization should consider in relation to spatiotemporal readiness and
the issues these provoke.
These and other issues are likely to arise, challenging both actual and anticipated spatiotemporal activities.
Focusing on spatiotemporal aspects implies recognizing infrastructure development as a fluid process that requires
constant planning, negotiation and maintenance. This attunes us to the interactivity of economic, infrastructural,
technical and regulatory aspects, as they influence and shape each other in complex ways across geographies and time
lines. It is vital that considerations of spatiotemporal issues are broad and multifaceted, as planning that focuses on
phases or processes in isolation misses broader socio-structural issues that affect the infrastructures of regenerative
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medicine. Spatiotemporal readiness is key to the deployment of emergent regenerative medicine therapies in clinical
settings and requires ongoing attention.
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